Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB) presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also presented details of its ongoing Phase 1 Trial 1201, evaluating CD38-SADA PRIT with Lu177-DOTA in adults with relapsed or refractory NHL. The trial consists of two parts: Part A focuses on dose escalation of CD38-SADA protein, while Part B aims to establish the optimal therapeutic dose of Lu177-DOTA. Both parts follow a 3+3 trial design with 4 planned dose levels.
Y-mAbs Therapeutics (NASDAQ: YMAB) ha presentato dati preclinici e progressi della sperimentazione per la sua piattaforma CD38-SADA durante il Congresso Annuale ASH 2024. I dati preclinici hanno dimostrato un legame selettivo e un'efficacia anti-tumorale del CD38-SADA quando utilizzato con Lutetium 177-DOTA nel trattamento del Linfoma Non-Hodgkin (NHL).
L'azienda ha anche presentato dettagli sul suo attuale Trial Fase 1 1201, che valuta CD38-SADA PRIT con Lu177-DOTA in adulti con NHL recidivante o refrattario. La sperimentazione consiste di due parti: la Parte A si concentra sull'escalation della dose di proteina CD38-SADA, mentre la Parte B ha come obiettivo l'ottimizzazione della dose terapeutica di Lu177-DOTA. Entrambe le parti seguono un design di prova 3+3 con 4 livelli di dosaggio pianificati.
Y-mAbs Therapeutics (NASDAQ: YMAB) presentó datos preclínicos y avances del ensayo de su plataforma CD38-SADA en la Reunión Anual ASH 2024. Los datos preclínicos demostraron una unión selectiva y eficacia antitumoral de CD38-SADA al ser utilizado junto con Lutecio 177-DOTA en el tratamiento del Linfoma No Hodking (NHL).
La compañía también presentó detalles sobre su Ensayo de Fase 1 1201, que evalúa CD38-SADA PRIT con Lu177-DOTA en adultos con NHL en recaída o refractario. El ensayo consta de dos partes: La Parte A se centra en la escalación de dosis de la proteína CD38-SADA, mientras que la Parte B tiene como objetivo establecer la dosis terapéutica óptima de Lu177-DOTA. Ambas partes siguen un diseño de ensayo 3+3 con 4 niveles de dosificación planificados.
Y-mAbs Therapeutics (NASDAQ: YMAB)는 2024 ASH 연례 회의에서 CD38-SADA 플랫폼에 대한 전임상 데이터 및 시험 진행 상황을 발표했습니다. 전임상 데이터는 비호지킨 림프종(NHL) 치료에 Lutetium 177-DOTA와 함께 사용할 때 CD38-SADA의 선택적 결합 및 항종양 효능을 입증했습니다.
회사는 재발성 또는 난치성 NHL 성인을 대상으로 Lu177-DOTA와 CD38-SADA PRIT을 평가하는 1상 시험 1201에 대한 세부정보를 발표했습니다. 이 시험은 두 부분으로 구성되어 있습니다: A 부분은 CD38-SADA 단백질의 용량 증량에 초점을 맞추고, B 부분은 Lu177-DOTA의 최적 치료 용량을 설정하는 것을 목표로 합니다. 두 부분 모두 3+3 시험 설계를 따르며 4개의 계획된 용량 수준이 있습니다.
Y-mAbs Therapeutics (NASDAQ: YMAB) a présenté des données précliniques et des avancées d'essai pour sa plateforme CD38-SADA lors de la Réunion Annuelle ASH 2024. Les données précliniques ont démontré une liaison sélective et une efficacité anti-tumorale de CD38-SADA lorsqu'il est utilisé avec Lutétium 177-DOTA dans le traitement du lymphome non hodgkinien (NHL).
La société a également présenté des détails sur son Essai de Phase 1 1201, évaluant CD38-SADA PRIT avec Lu177-DOTA chez les adultes ayant un NHL en rechute ou réfractaire. L'essai se compose de deux parties : la Partie A se concentre sur l'escalade de la dose de la protéine CD38-SADA, tandis que la Partie B vise à établir la dose thérapeutique optimale de Lu177-DOTA. Les deux parties suivent un design d'essai 3+3 avec 4 niveaux de dose prévus.
Y-mAbs Therapeutics (NASDAQ: YMAB) hat auf dem ASH-Jahrestreffen 2024 präklinische Daten und Fortschritte bei seiner CD38-SADA-Plattform vorgestellt. Die präklinischen Daten zeigten eine selektive Bindung und anti-tumorale Wirksamkeit von CD38-SADA in Kombination mit Lutetium 177-DOTA bei der Behandlung von Non-Hodgkin-Lymphom (NHL).
Das Unternehmen präsentierte auch Einzelheiten zu seiner laufenden Phase-1-Studie 1201, die CD38-SADA PRIT mit Lu177-DOTA bei Erwachsenen mit rückfälligem oder refraktärem NHL bewertet. Die Studie besteht aus zwei Teilen: Teil A konzentriert sich auf die Dosissteigerung des CD38-SADA-Proteins, während Teil B darauf abzielt, die optimale therapeutische Dosis von Lu177-DOTA festzulegen. Beide Teile folgen einem 3+3-Studiendesign mit 4 geplanten Dosen.
- Preclinical data showed positive anti-tumor efficacy in NHL treatment
- Successfully initiated Phase 1 clinical trial for CD38-SADA PRIT
- Demonstrated dose-dependent tumor responses in xenograft mouse models
- None.
Insights
The presentation of CD38-SADA preclinical data represents an incremental step in Y-mAbs' development of their radioimmunotherapy platform. The preclinical results showing dose-dependent tumor responses in xenograft models provide early validation, but are very preliminary. The initiation of Trial 1201 marks the platform's first application in hematological cancers, expanding beyond solid tumors.
The two-step PRIT approach using CD38-SADA with Lu177-DOTA is scientifically interesting, targeting CD38 which is highly expressed in lymphomas. However, this is still very early stage - a Phase 1 safety study with a basic 3+3 dose escalation design. While the technology shows promise, meaningful clinical data is likely years away.
For context, radioimmunotherapy in lymphomas isn't new - Zevalin and Bexxar were previous commercial products, though both faced challenges. The SADA platform's potential advantages in targeting and clearance would need to be clearly demonstrated in clinical trials to differentiate it.
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition being held on December 7 –10, 2024, in San Diego, California.
A poster titled “CD38-SADA, a Self-Assembling and Dis-Assembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma” characterizes the selective binding of CD38-SADA to DOTA-chelated lanthanide metals and high-avidity binding to CD38, a tumor specific antigen overexpressed across a range of lymphoma cells. Data from this poster demonstrate anti-tumor efficacy of CD38-SADA when used with Lutetium 177 (Lu177)-DOTA in a two-step approach to pre-targeted radioimmunotherapy (“PRIT”). Tumor responses in a xenograft mouse model were rapid and dose-dependent, further supporting the clinical development of CD38-SADA PRIT in patients with CD38-positive lymphoid malignancies.
“This preclinical analysis provides important insights into the unique pharmacology of CD38-SADA and its therapeutic potential for NHL,” said Brian H. Santich, Ph.D., the lead author and co-inventor of the SADA PRIT technology platform. “The anti-tumor efficacy positively correlated with increasing doses of Lu177-DOTA and CD38-SADA, which informed the study design and initial dosing regimen of our Trial 1201 in patients with NHL.”
In addition, Y-mAbs presents a trial-in-progress poster from its ongoing Phase 1 (Trial 1201) clinical study evaluating the safety and tolerability of CD38-SADA PRIT with Lu177-DOTA in adults with relapsed or refractory NHL. Trial 1201 is a first-in-human, dose-escalation, open-label, multicenter study composed of two parts. Part A includes dose escalation of the CD38-SADA bispecific fusion protein to define the optimal safe dose of the CD38-SADA protein, the administration interval between CD38-SADA and Lu177-DOTA, and the Lu177-DOTA dose for tumor imaging. In Part B, dose escalation of Lu177-DOTA will establish the optimal therapeutic dose of the radioactive payload. For each part, the escalation is based on a 3+3 trial design of 4 planned dose levels.
“We are pleased to share the details of this Phase 1 clinical trial, which is investigating a potentially transformative approach to pre-targeted radioimmunotherapy for patients with relapsed and refractory NHL,” said Vignesh Rajah, MBBS, DCH, MRCP (UK), Chief Medical Officer. “This is our second clinical program evaluating the SADA PRIT technology platform and our first in hematological malignancies.”
The abstract details are below:
Abstract Title: “CD38-SADA, a Self-Assembling and Dis-Assembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma”
Format: Poster Presentation, ID: 1599
Date and Time: Saturday, December 7, 2024, 5:30 PM-7:30 PM
Abstract Title: “CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial”
Format: Poster Presentation, ID: 4434.1
Date and Time: Monday, December 9, 2024, 6:00 PM-8:00 PM
Researchers at Memorial Sloan Kettering Cancer Center (MSK), including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. Dr. Cheung has intellectual property rights and interests in the technology, and as a result of this licensing arrangement, MSK has institutional financial interests in the technology.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
About CD38-SADA PRIT
CD38-SADA is a bispecific fusion protein that tightly binds to the CD38 antigen and to select radionuclides chelated to tetraxetan (or “DOTA”). CD38-SADA contains a p53-derived domain that drives the self-assembly of CD38-SADA tetramers, which possess four distinct binding sites for CD38. In the first step of pre-targeted radiotherapy, non-radiolabeled-CD38-SADA tetramers are infused and bind with high avidity to CD38-positive tumors, while unbound CD38-SADA disassembles into low molecular weight monomers that are removed by the kidney. The second infusion delivers the “radioactive payload,” which binds to the CD38-SADA on tumor cells for localized irradiation. CD38-SADA PRIT with Lutetium 177 (Lu 177)-DOTA is now under clinical investigation in Trial 1201 (NCT05994157).
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond, including estimated operating expenses, use of cash and cash equivalents and DANYELZA product revenue and sufficiency of cash resources and related assumptions; expectations with respect to the Company’s future financial performance; implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals; expectations with respect to the Company’s plans and strategies, development, regulatory, commercialization and product distribution plans, including the timing thereof; expectations with respect to the Company’s products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA PRIT technology and potential benefits and applications thereof; expectations relating to key anticipated development milestones, including potential expansion and advancement of commercialization and development efforts, including potential indications, applications and geographies, and the timing thereof; expectations with respect to current and future clinical and pre-clinical studies and the Company’s research and development programs, including with respect to timing and results; expectations regarding collaborations or strategic partnerships and the potential benefits thereof; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s or its partners’ regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture as well as regulatory submissions; the Company’s ability to enter into new partnerships or to recognize the anticipated benefits from its existing partnerships; risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
SADA®, SADA PRIT®, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
FAQ
What are the key findings of Y-mAbs (YMAB) CD38-SADA preclinical trials for NHL treatment?
What is the structure of Y-mAbs (YMAB) Phase 1 Trial 1201 for CD38-SADA PRIT?
When did Y-mAbs (YMAB) present their CD38-SADA data at ASH 2024?
